Developer docs
API playgroundTry for free, no card

Search company profiles

Adaptive Phage Therapeutics

Full company profile

uuid0000xog

Namestring
Adaptive Phage Therapeutics
Legal namestring
Adaptive Phage Therapeutics
Websiteurl
aphage.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBethesda, United States
HQ citystring
Bethesda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bacteriophage therapy, phage-based therapeutics, antibiotic-resistant infections, precision phage therapy, multi-drug resistant bacteria
Industry1 code
PRIMARYHLAAAFAF
Phage & Phage-Derived Microbiome Modulators
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Phage-Based Therapeutics
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for treating multi-drug resistant bacterial infections. Its core offering, PhageBank™, is a proprietary library of bacteriophages that can be rapidly matched to specific bacterial pathogens to deliver targeted phage-based treatments. The company was advancing Phase 1/2 clinical trials for diabetic foot osteomyelitis before being acquired by BiomX Ltd. in March 2024.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for antibiotic-resistant bacterial infections. The company's primary offering is the PhageBank™ platform, which provides phage-based treatments designed to target and eliminate drug-resistant bacteria. The company was acquired by BiomX Ltd. in March 2024.

Product and service1 record
1PhageBank™
CategoryBacteriophage Therapy Platform
Description

PhageBank™ is a proprietary precision bacteriophage therapy platform and library designed to target multi-drug resistant bacterial infections. It enables rapid matching of phage cocktails to specific bacterial pathogens for clinical use, with development focused on indications such as diabetic foot osteomyelitis.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

BiomX Ltd., an Israeli firm, acquired Adaptive Phage Therapeutics in March 2024. This acquisition represents a strategic consolidation in the phage therapy sector, with BiomX expanding its capabilities through the acquisition of this US-based clinical-stage biotechnology company specializing in precision bacteriophage therapies.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Acquirer and parent company of Adaptive Phage Therapeutics; Israeli clinical-stage biotech developing phage-based therapeutics targeting AMR-related bacterial infections, with overlapping pipeline in cystic fibrosis and other indications.

TypeDirect peer
Description

Clinical-stage phage therapy company developing engineered bacteriophage cocktails for antibiotic-resistant infections including Pseudomonas aeruginosa and Staphylococcus aureus; directly comparable therapeutic platform and AMR focus.

TypeDirect peer
Description

Clinical-stage biotech developing direct lytic agents (lysins) and other novel antimicrobials for serious antibiotic-resistant infections, including MRSA bacteremia; competes in the same therapeutic area with adjacent biological modality.

TypeDirect peer
Description

Clinical-stage company developing engineered bacteriophage products, including CRISPR-enhanced phage therapies, for treatment of antibiotic-resistant bacterial infections; overlapping platform technology and clinical development stage.

TypeEmerging player
Description

Developer of phage-based precision medicines using engineered payloads (e.g., CRISPR) to selectively target pathogenic bacteria; earlier-stage but directly comparable platform approach for microbiome and AMR applications.

TypeDirect peer
Description

French clinical-stage biotech developing phage therapy products targeting antibiotic-resistant bacterial infections, including Pseudomonas and Staph aureus; comparable clinical-stage phage therapy pipeline in Europe.

TypeRegional player
Description

Portuguese clinical-stage biotech developing bacteriophage-based products for bacterial infections; comparable therapeutic modality and AMR focus, primarily serving European markets.

TypeEmerging player
Description

Clinical-stage company developing CRISPR-based phage products (SNIPR001) to target antimicrobial-resistant bacteria in the gut of immunocompromised patients; adjacent modality with overlapping AMR application.

TypeEmerging player
Description

UK-based biotech developing novel antimicrobial approaches including Antibody-Bactericidal Conjugates targeting serious drug-resistant infections; comparable AMR focus with adjacent biological modality.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adaptive Phage Therapeutics

Phage-Based Therapeuticsaphage.com

Adaptive Phage Therapeutics firmographics

Firmographics
Name
Adaptive Phage Therapeutics
Legal name
Adaptive Phage Therapeutics
Website
https://aphage.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

Adaptive Phage Therapeutics industry classification

Industry
Product category
Phage-Based Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAF
Phage & Phage-Derived Microbiome Modulators

Keywords

  • Bacteriophage therapy
  • Phage-based therapeutics
  • Antibiotic-resistant infections
  • Precision phage therapy
  • Multi-drug resistant bacteria

Where Adaptive Phage Therapeutics is headquartered

Location

Headquarters

HQ city
Bethesda
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Adaptive Phage Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Adaptive Phage Therapeutics product offering

Product offering

Core offering

Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for treating multi-drug resistant bacterial infections. Its core offering, PhageBank™, is a proprietary library of bacteriophages that can be rapidly matched to specific bacterial pathogens to deliver targeted phage-based treatments. The company was advancing Phase 1/2 clinical trials for diabetic foot osteomyelitis before being acquired by BiomX Ltd. in March 2024.

Product overview

Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for antibiotic-resistant bacterial infections. The company's primary offering is the PhageBank™ platform, which provides phage-based treatments designed to target and eliminate drug-resistant bacteria. The company was acquired by BiomX Ltd. in March 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • PhageBank™ PhageBank™ is a proprietary precision bacteriophage therapy platform and library designed to target multi-drug resistant bacterial infections. It enables rapid matching of phage cocktails to specific bacterial pathogens for clinical use, with development focused on indications such as diabetic foot osteomyelitis.

Companies that use Adaptive Phage Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Adaptive Phage Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Adaptive Phage Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BiomX Ltd.coreOthersBiomX Ltd., an Israeli firm, acquired Adaptive Phage Therapeutics in March 2024. This acquisition represents a strategic consolidation in the phage therapy sector, with BiomX expanding its capabilities through the acquisition of this US-based clinical-stage biotechnology company specializing in precision bacteriophage therapies.

Scale indicators5 records

Recent moves4 records

Expansion highlights4 records

Adaptive Phage Therapeutics competitors and assessment

Company assessment

Direct peers

  • BiomX Ltd. Acquirer and parent company of Adaptive Phage Therapeutics; Israeli clinical-stage biotech developing phage-based therapeutics targeting AMR-related bacterial infections, with overlapping pipeline in cystic fibrosis and other indications.
  • Armata Pharmaceuticals: Clinical-stage phage therapy company developing engineered bacteriophage cocktails for antibiotic-resistant infections including Pseudomonas aeruginosa and Staphylococcus aureus; directly comparable therapeutic platform and AMR focus.
  • ContraFect Corporation: Clinical-stage biotech developing direct lytic agents (lysins) and other novel antimicrobials for serious antibiotic-resistant infections, including MRSA bacteremia; competes in the same therapeutic area with adjacent biological modality.
  • Locus Biosciences: Clinical-stage company developing engineered bacteriophage products, including CRISPR-enhanced phage therapies, for treatment of antibiotic-resistant bacterial infections; overlapping platform technology and clinical development stage.
  • Pherecydes Pharma: French clinical-stage biotech developing phage therapy products targeting antibiotic-resistant bacterial infections, including Pseudomonas and Staph aureus; comparable clinical-stage phage therapy pipeline in Europe.

Emerging players

  • Eligo Bioscience: Developer of phage-based precision medicines using engineered payloads (e.g., CRISPR) to selectively target pathogenic bacteria; earlier-stage but directly comparable platform approach for microbiome and AMR applications.
  • SNIPR Biome: Clinical-stage company developing CRISPR-based phage products (SNIPR001) to target antimicrobial-resistant bacteria in the gut of immunocompromised patients; adjacent modality with overlapping AMR application.
  • Centauri Therapeutics: UK-based biotech developing novel antimicrobial approaches including Antibody-Bactericidal Conjugates targeting serious drug-resistant infections; comparable AMR focus with adjacent biological modality.

Regional players

  • TechnoPhage: Portuguese clinical-stage biotech developing bacteriophage-based products for bacterial infections; comparable therapeutic modality and AMR focus, primarily serving European markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks3 records

Key highlights5 records

Customer concentration

Adaptive Phage Therapeutics social profiles

Digital presence

Adaptive Phage Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adaptive Phage Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Adaptive Phage Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adaptive Phage Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adaptive Phage Therapeutics

What does Adaptive Phage Therapeutics do?

Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for treating multi-drug resistant bacterial infections. Its core offering, PhageBank™, is a proprietary library of bacteriophages that can be rapidly matched to specific bacterial pathogens to deliver targeted phage-based treatments. The company was advancing Phase 1/2 clinical trials for diabetic foot osteomyelitis before being acquired by BiomX Ltd. in March 2024.

Is Adaptive Phage Therapeutics a public or private company?

Adaptive Phage Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Adaptive Phage Therapeutics founded?

Adaptive Phage Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Adaptive Phage Therapeutics based?

Adaptive Phage Therapeutics is headquartered in Bethesda, United States, in the North America region.

Who are Adaptive Phage Therapeutics's main competitors?

Direct peers on record are BiomX Ltd., Armata Pharmaceuticals, ContraFect Corporation, Locus Biosciences and Pherecydes Pharma. Emerging players are Eligo Bioscience, SNIPR Biome and Centauri Therapeutics. TechnoPhage is listed as a regional player.

Does Adaptive Phage Therapeutics have an API?

No public API is recorded for Adaptive Phage Therapeutics.

What industry is Adaptive Phage Therapeutics in?

Adaptive Phage Therapeutics's product category is Phage-Based Therapeutics. Its primary akta.pro industry code is HLAAAFAF, Phage & Phage-Derived Microbiome Modulators. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBacteriophage Therapy - Global Strategic Business Report 2026: Capture the $1.6 Billion 2032 Market with Adaptive Phage Therapeutics, Armata Pharmaceuticals, BiomX, and Locus BiosciencesThe global bacteriophage therapy market was valued at US$1.3 billion in 2025 and is projected to reach US$1.6 billion by 2032, a CAGR of 3.0%. Growth is driven by antimicrobial resistance and advances in genomic technologies, with the U.S. market at US$351.1 million in 2025.openPR.comCompetitive Landscape: Key Market Leaders and New Entrants in the Osteomyelitis MarketThe Business Research Company published a market report projecting the osteomyelitis market will reach $1.69 billion by 2030, growing at a compound annual growth rate of 8.7%. In March 2024, Israel-based biotech firm BiomX Inc. acquired Adaptive Phage Therapeutics Inc., a US-based company specializing in phage therapy for osteomyelitis, particularly diabetic foot infections. The report highlights key growth drivers including innovative antibiotic development, antimicrobial resistance management, and expanded outpatient antibiotic therapy programs.openPR.comTop Players and Competitive Dynamics in the Pseudomonas Aeruginosa Infection Treatment MarketThe global Pseudomonas aeruginosa infection treatment market is projected to reach $3.89 billion by 2030, growing at a compound annual growth rate of 8.0%. In March 2024, Israeli firm BiomX Ltd. acquired US-based Adaptive Phage Therapeutics to establish a leading phage therapy company focused on bacterial infections including chronic pulmonary infections in cystic fibrosis patients. Additionally, in June 2023, Japan's Shionogi & Co. Ltd. partnered with Switzerland-based GARDP and US-based CHAI to improve global access to cefiderocol, an antibiotic for severe Gram-negative bacterial infections.GlobeNewswirePhage Therapies Market Research and Competitive Landscape Report 2026: Over 20 Companies and 22 Drugs by Product Type, Stage, Administration Route, and Molecule TypeResearch and Markets released its 'Phage Therapies - Competitive Landscape, 2026' report covering over 20 companies and 22 drugs in the phage therapy market, an emerging field targeting antibiotic-resistant bacteria through bacteriophage technology. Key recent developments include PHAXIAM Therapeutics reporting a 74% infection control rate from its PhagoDAIR I pilot study, Locus Biosciences showing favorable Phase II trial data for LBP-EC01, and Armata Pharmaceuticals receiving $5.25 million in Department of Defense funding. BiomX's acquisition of Adaptive Phage Therapeutics in March 2024 also highlights ongoing consolidation in the sector.Market ScoopBacteriophage MarketA market research report projects the global bacteriophage market to grow from US$ 1.1 billion in 2024 to US$ 2.0 billion by 2034, driven primarily by rising antimicrobial resistance and increased government funding for phage-based therapies. Key developments include Locus Biosciences reporting favorable Phase 2 trial results for its CRISPR-enhanced phage therapy and BiomX completing a merger with Adaptive Phage Therapeutics to consolidate their pipelines.GlobeNewswireBiomX Announces the Appointment of Susan Blum to its Board of DirectorsBiomX appointed Susan Blum to its Board of Directors, making her chair of the audit committee. She brings CFO experience from Melinta Therapeutics and will help guide integration of Adaptive Phage Therapeutics and advance clinical programs BX004 and BX211.GlobeNewswireBiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateBiomX reported Q4 and full-year 2023 results, including a $26.2 million net loss and $15.9 million cash balance. The company closed a $50 million financing and acquired Adaptive Phage Therapeutics, adding BX211 for diabetic foot osteomyelitis. Topline results for BX211 are expected in Q1 2025.